arrow
A

Austin Miller

university of victoria
H指数:47
被引数:9,599

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120

更正:Oturkar等人。雌激素受体-Beta2(ERβ2)-突变p53-FOXM1轴:高级别浆液性卵巢癌(HGSOC)中增殖、化疗耐药和疾病进展的新型驱动因素。Cancers 2022, 14, 1120

Cancers
IF4.4
2026-07-230
OAAI
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

实用妇科癌症临床试验:妇科癌症协作组芝加哥头脑风暴会议的声明与路线图

2026-06-230
OAAI
Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
2023-10-013
PRE
Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
2023-10-017
PRE
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2023-01-0318
OAAI
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
2022-07-012
OAAI
Survival With Cemiplimab in Recurrent Cervical Cancer
2022-06-011
PRE
Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
2021-09-014
OAAI
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
2021-07-0133
OAAI
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
2021-03-178
OAAI
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
2020-09-0127
OAAI
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

全基因组关联研究从总体和亚型特异性分析中确定了32个新的乳腺癌易感位点

2020-05-18143
OAAI